Sully, I concur with your post 100%. Zacks's opinion is worth considering too.
"Meanwhile, Ariad Pharmaceuticals is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
In fact, over the past month, current quarter estimates have narrowed from a loss of 30 cents per share to a loss of 28 cents per share, while current year estimates have narrowed from a loss of $1.21 per share to a loss of $1.20 per share. The company currently holds a Zacks Rank #3 (Hold), which is also a favorable signal."